Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis

4,6,4′-trimethylangelicin (TMA) is a promising pharmacological option for the treatment of cystic fibrosis (CF) due to its triple-acting behavior toward the function of the CF transmembrane conductance regulator. It is a poorly water-soluble drug, and thus it is a candidate for developing a self-emu...

Descripción completa

Detalles Bibliográficos
Autores principales: Franceschinis, Erica, Roverso, Marco, Gabbia, Daniela, De Martin, Sara, Brusegan, Matteo, Vaccarin, Christian, Bogialli, Sara, Chilin, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506254/
https://www.ncbi.nlm.nih.gov/pubmed/36145554
http://dx.doi.org/10.3390/pharmaceutics14091806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506254/
https://www.ncbi.nlm.nih.gov/pubmed/36145554
http://dx.doi.org/10.3390/pharmaceutics14091806

Ejemplares similares